AU2008237935B2 - Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy - Google Patents

Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy Download PDF

Info

Publication number
AU2008237935B2
AU2008237935B2 AU2008237935A AU2008237935A AU2008237935B2 AU 2008237935 B2 AU2008237935 B2 AU 2008237935B2 AU 2008237935 A AU2008237935 A AU 2008237935A AU 2008237935 A AU2008237935 A AU 2008237935A AU 2008237935 B2 AU2008237935 B2 AU 2008237935B2
Authority
AU
Australia
Prior art keywords
alkyl
independently
hal
alkoxy
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008237935A
Other languages
English (en)
Other versions
AU2008237935A1 (en
Inventor
Viola Groehn
Urs Michel
Thomas Leighton Mindt
Rudolf Moser
Cristina Magdalena Muller
Roger Schibli
Christof Sparr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck & Cie
Original Assignee
Merck & Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Cie filed Critical Merck & Cie
Publication of AU2008237935A1 publication Critical patent/AU2008237935A1/en
Assigned to Merck & Cie reassignment Merck & Cie Alteration of Name(s) of Applicant(s) under S113 Assignors: MERCK EPROVA AG
Application granted granted Critical
Publication of AU2008237935B2 publication Critical patent/AU2008237935B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/22—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by measuring secondary emission from the material
    • G01N23/2204—Specimen supports therefor; Sample conveying means therefore
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Radiation-Therapy Devices (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nuclear Medicine (AREA)
AU2008237935A 2007-04-11 2008-04-11 Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy Ceased AU2008237935B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07105980 2007-04-11
EP07105980.2 2007-04-11
PCT/EP2008/054409 WO2008125618A1 (en) 2007-04-11 2008-04-11 Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy

Publications (2)

Publication Number Publication Date
AU2008237935A1 AU2008237935A1 (en) 2008-10-23
AU2008237935B2 true AU2008237935B2 (en) 2014-03-27

Family

ID=39683755

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008237935A Ceased AU2008237935B2 (en) 2007-04-11 2008-04-11 Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy

Country Status (11)

Country Link
US (2) US20100143249A1 (enExample)
EP (1) EP2146995A1 (enExample)
JP (2) JP5710246B2 (enExample)
KR (2) KR101605426B1 (enExample)
CN (1) CN101646672B (enExample)
AU (1) AU2008237935B2 (enExample)
CA (1) CA2670385C (enExample)
EA (1) EA200901344A1 (enExample)
IL (1) IL201250A0 (enExample)
WO (1) WO2008125618A1 (enExample)
ZA (1) ZA200903483B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100143249A1 (en) * 2007-04-11 2010-06-10 Merck Eprova Ag Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy
US8236284B1 (en) * 2008-04-02 2012-08-07 University Of Central Florida Research Foundation, Inc. Multimodal, multifunctional polymer coated nanoparticles
FR2942227B1 (fr) * 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
WO2011084571A2 (en) 2009-12-16 2011-07-14 Mallinckrodt Inc. Azide derivatives for phototherapy
DK2766364T3 (da) * 2011-08-17 2024-09-30 Merck & Cie Folatkonjugater af albumin-bindende enheder
AU2013258027B2 (en) 2012-05-08 2017-11-30 Merck & Cie 18F-labelled follate/antifolate analogues
CN107207418A (zh) * 2015-02-06 2017-09-26 森普拉制药公司 4‑叠氮基丁胺和制备方法
JP7391847B2 (ja) 2019-06-20 2023-12-05 クワッド マイナーズ ネットワークフォレンジックシステム及びこれを用いたネットワークフォレンジック方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059640A2 (en) * 1998-05-16 1999-11-25 Bracco International B.V. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
WO2003092742A1 (en) * 2002-05-06 2003-11-13 Endocyte, Inc. Vitamin-targeted imaging agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
WO2004097406A2 (en) * 2003-04-29 2004-11-11 Universität Zürich Nϵ AND/OR Nα DERIVATIZED, METAL AND ORGANIC PROTECTED L-HISTIDINE FOR COUPLING TO BIOMOLECULES FOR HIGHLY EFFICIENT LABELING WITH [M(OH2)3(CO)3]+ BY FAC COORDINATION
US9265746B2 (en) * 2006-05-31 2016-02-23 Merck & Cie Method for cell-specific targeting
US20100143249A1 (en) * 2007-04-11 2010-06-10 Merck Eprova Ag Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059640A2 (en) * 1998-05-16 1999-11-25 Bracco International B.V. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US20010004454A1 (en) * 1998-05-16 2001-06-21 Wedeking Paul W. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
WO2003092742A1 (en) * 2002-05-06 2003-11-13 Endocyte, Inc. Vitamin-targeted imaging agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KE CHUN-YEN et al: Nuclear Medicine & Biology, 2003, 30(8), 811-817 *
MINDT T. L. et al: J American Chem. Soc., 2006, 128, 15096-15097 *

Also Published As

Publication number Publication date
CA2670385C (en) 2016-01-12
ZA200903483B (en) 2010-04-28
JP5876527B2 (ja) 2016-03-02
US20170128599A1 (en) 2017-05-11
HK1138571A1 (zh) 2010-08-27
WO2008125618A1 (en) 2008-10-23
US20100143249A1 (en) 2010-06-10
CN101646672B (zh) 2015-08-19
KR20150140415A (ko) 2015-12-15
KR20100016330A (ko) 2010-02-12
KR101605426B1 (ko) 2016-03-22
AU2008237935A1 (en) 2008-10-23
CA2670385A1 (en) 2008-10-23
EA200901344A1 (ru) 2010-04-30
EP2146995A1 (en) 2010-01-27
IL201250A0 (en) 2010-05-31
JP2014193889A (ja) 2014-10-09
JP5710246B2 (ja) 2015-04-30
JP2010523626A (ja) 2010-07-15
CN101646672A (zh) 2010-02-10

Similar Documents

Publication Publication Date Title
AU2008237932B2 (en) 18 F-labelled folates
US20170128599A1 (en) Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy
AU2013258027B2 (en) 18F-labelled follate/antifolate analogues
US9771368B2 (en) 18F-labelled folates
JP5730771B2 (ja) Ｐｅｔ用放射性トレーサーとしての１８ｆ標識葉酸
HK1138571B (en) Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired